The role of CD73 in cancer: validating a novel therapeutic target

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1007902

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We here propose to investigate the role of a specific immune-suppressive molecule called CD73 in cancer. We will test the therapeutic activity of blocking CD73 with a monoclonal antibody for cancer treatment, either used alone or in combination with immune-activating agents and chemotherapy.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: Project Grants

Funding Amount: $540,356.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

adenosine | adenosine receptors | breast cancer metastases | cancer biology | cancer immunotherapy | immune regulation | immunotherapy | tumour immunology

Related Links